Published :
Tables : 52
Figures : 47
Category : Healthcare
No. of Pages : 233
Report Code : HC-U3128
Global Vaccines Market is estimated to value over CAGR of over 6.8% during the forecast period 2022 to 2028. The vaccines market growth can be credited to a rise in the occurrence of infectious diseases, increased financial support from the government for developing vaccines, rising emphasis on immunization, increased research and development activities in enhancing the vaccines. Conversely, the requirement of capital investments for the development of vaccines is huge which shall impede the growth of the market. The market is fragmented into technology, type, disease indication, route of administration, patient type and region. The technology segment is categorised into inactivated and subunit vaccines, conjugate vaccines, recombinant vaccines, live attenuated vaccines, toxoid vaccines and recombinant vaccines. The conjugate vaccines held the largest vaccines market share, and this can be primarily credited to a rise in the support of the government, increase in the investments made by key players in developing conjugate vaccines. Based on the route of administration, the market is fragmented into oral administration, intramuscular and subcutaneous administration and other routes of administration. The intramuscular and subcutaneous administration is predicted to proliferate during the forecast period, and this is mainly due to its capability of providing a lower injection site reaction rate and a good immune response. Major players included in the Vaccines Market are: GLAXOSMITHKLINE PLC PFIZER INC. MERCK & CO. INC SANOFI PASTEUR SA CSL LIMITED EMERGENT BIOSOLUTIONS JOHNSON & JOHNSON ASTRAZENECA SERUM INSTITUTE OF INDIA PVT. LTD BAVARIAN NORDIC MITSUBISHI TANABE PHARMA CORP. DAIICHI SANKYO CO. LTD. PANACEA BIOTEC LTD. BIOLOGICAL E LTD. BHARAT BIOTECH (Note: The list of the major players will be updated with the latest market scenario and trends) Vaccines Market Segmentation: By Technology Conjugate Vaccines Inactive and Subunit Vaccines Live Attenuated Vaccines Recombinant Vaccines Toxoid Vaccines By Type Monovalent Vaccines Multivalent Vaccines By Disease Indication Pneumococcal Disease DTP Influenza HPV Meningococcal Disease Polio Hepatitis Rotavirus MMR Varicella Herpes Zoster Others By Route of Administration Intramuscular and Subcutaneous Administration Oral Administration Others By Patient Type Pediatric Patients Adult Patients Others By Region North America Europe Asia-Pacific Latin America Middle East and Africa Regional Analysis: The North America region is predicted to dominate the global market, and this is mainly due to a high occurrence of infectious disorders and rising investments by private and public organizations for developing vaccines and a strong presence of key market players in the region. The Asia Pacific region is expected to project the highest growth and this mainly due to rise in the disposable income leading to an increased healthcare expenditure, increase in the patient pool and growing initiatives by the government. Competitive Landscape: The prominent market players are GlaxoSmithKline plc., Pfizer, Inc. Merck & Co., Inc., Sanofi Pasteur SA, CSL Limited, Emergent BioSolutions, Inc., Johnson & Johnson, Serum Institute of India, AstraZeneca, Bavarian Nordic, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company, Limited. The Impact of COVID-19 on Vaccines Market: Major pharmaceutical companies are creating strategic alliances to develop vaccines for treating COVD-19. For instance, Sanofi and GlaxoSmithKline have partnered to launch a vaccine for novel coronavirus during the second half of 2020. Sanofi will use its S-protein antigen that has produced a protein that genetically matches with the protein present on the surface of the novel coronavirus while GlaxoSmithKline will offer their pandemic adjuvant technology, an immunological agent that is added to a vaccine in order to boost its immune response and produce long-lasting immunity and more antibodies. Furthermore, Novavax, a biotechnology company based in USA, is planning to partner with Nucleus Network, an Australian company specialized in clinical trials, to initiate the testing of the NVX-CoV2373 vaccine and this will be the first vaccine for COVID-19 to be tested outside the United States. Novavax previously made efforts in developing vaccines for SARS and MERS. This experience shall assist them in developing a vaccine for COVID-19. FutureWise Key Takeaways: Growth prospects SWOT analysis Key trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the Vaccines Market By Technology, By Type, By Disease Indication, By Route of Administration, By Patient Type and By Region. To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization Mobility Care offered are free of charge with purchase of any license of the report You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
The vaccines market growth can be credited to a rise in the occurrence of infectious diseases, increased financial support from the government for developing vaccines, rising emphasis on immunization, increased research and development activities in enhancing the vaccines. Conversely, the requirement of capital investments for the development of vaccines is huge which shall impede the growth of the market.
The market is fragmented into technology, type, disease indication, route of administration, patient type and region. The technology segment is categorised into inactivated and subunit vaccines, conjugate vaccines, recombinant vaccines, live attenuated vaccines, toxoid vaccines and recombinant vaccines. The conjugate vaccines held the largest vaccines market share, and this can be primarily credited to a rise in the support of the government, increase in the investments made by key players in developing conjugate vaccines. Based on the route of administration, the market is fragmented into oral administration, intramuscular and subcutaneous administration and other routes of administration. The intramuscular and subcutaneous administration is predicted to proliferate during the forecast period, and this is mainly due to its capability of providing a lower injection site reaction rate and a good immune response. Major players included in the Vaccines Market are:
(Note: The list of the major players will be updated with the latest market scenario and trends) Vaccines Market Segmentation: By Technology
By Type
By Disease Indication
By Route of Administration
By Patient Type
By Region
Regional Analysis: The North America region is predicted to dominate the global market, and this is mainly due to a high occurrence of infectious disorders and rising investments by private and public organizations for developing vaccines and a strong presence of key market players in the region. The Asia Pacific region is expected to project the highest growth and this mainly due to rise in the disposable income leading to an increased healthcare expenditure, increase in the patient pool and growing initiatives by the government.
Competitive Landscape:
The prominent market players are GlaxoSmithKline plc., Pfizer, Inc. Merck & Co., Inc., Sanofi Pasteur SA, CSL Limited, Emergent BioSolutions, Inc., Johnson & Johnson, Serum Institute of India, AstraZeneca, Bavarian Nordic, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company, Limited.
The Impact of COVID-19 on Vaccines Market: Major pharmaceutical companies are creating strategic alliances to develop vaccines for treating COVD-19. For instance, Sanofi and GlaxoSmithKline have partnered to launch a vaccine for novel coronavirus during the second half of 2020. Sanofi will use its S-protein antigen that has produced a protein that genetically matches with the protein present on the surface of the novel coronavirus while GlaxoSmithKline will offer their pandemic adjuvant technology, an immunological agent that is added to a vaccine in order to boost its immune response and produce long-lasting immunity and more antibodies. Furthermore, Novavax, a biotechnology company based in USA, is planning to partner with Nucleus Network, an Australian company specialized in clinical trials, to initiate the testing of the NVX-CoV2373 vaccine and this will be the first vaccine for COVID-19 to be tested outside the United States. Novavax previously made efforts in developing vaccines for SARS and MERS. This experience shall assist them in developing a vaccine for COVID-19.
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data From Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data From Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Global Vaccines Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards And Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Pharmaceutical Manufacturers on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Vaccines Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Vaccines Market , By Technology Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Conjugate Vaccines 7.2. Inactive and Subunit Vaccines 7.3. Live Attenuated Vaccines 7.4. Recombinant Vaccines 7.5. Toxoid Vaccines 8. Global Vaccines Market , By Type Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Monovalent Vaccines 8.2. Multivalent Vaccines 9. Global Vaccines Market , By Disease Indication Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Pneumococcal Disease 9.2. DTP 9.3. Influenza 9.4. HPV 9.5. Meningococcal Disease 9.6. Polio 9.7. Hepatitis 9.8. Rotavirus 9.9. MMR 9.10. Varicella 9.11. Herpes Zoster 9.12. Others 10. Global Vaccines Market , By Route of Administration Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Intramuscular and Subcutaneous Administration 10.2. Oral Administration 10.3. Others 11. Global Vaccines Market , By Patient Type Historical Analysis and Forecast 2022-2028 (USD Million) 11.1. Pediatric Patients 11.2. Adult Patients 11.3. Others 12. North America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. U.S.A 12.2.2. Canada 12.3. Market Size (USD Million) Forecast for North America 2022-2028 13. Latin America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 13.1. Introduction 13.2. Regional Market Trends 13.3. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.3.1. Brazil 13.3.2. Mexico 13.3.3. Argentina 13.3.4. Rest of Latin America 13.4. Market Size (USD Million) Forecast for Latin America 2022-2028 14. Europe Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Germany 14.2.2. U.K 14.2.3. France 14.2.4. Italy 14.2.5. Spain 14.2.6. Russia 14.2.7. Poland 14.2.8. Switzerland 14.2.9. Rest of Western Europe 15. Asia Pacific Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. Japan 15.2.2. China 15.2.3. Singapore 15.2.4. India 15.2.5. Australia and New Zealand 15.2.6. ASEAN 15.2.7. South Korea 15.2.8. Rest of Asia Pacific 15.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 16. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 16.1. Introduction 16.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 16.2.1. GCC 16.2.2. Israel 16.2.3. South Africa 16.2.4. Rest of MEA 16.3. Market Size (USD Million) Forecast for MEA 2022-2028 17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts) 17.1 GLAXOSMITHKLINE PLC 17.1.1. Company Overview 17.1.2. Product Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2 PFIZER INC. 17.2.1. Company Overview 17.2.2. Product Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3 MERCK & CO. INC. 17.3.1. Company Overview 17.3.2. Product Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4 SANOFI PASTEUR SA 17.4.1. Company Overview 17.4.2. Product Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5 CSL LIMITED 17.5.1. Company Overview 17.5.2. Product Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6 EMERGENT BIOSOLUTIONS 17.6.1. Company Overview 17.6.2. Product Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7 JOHNSON & JOHNSON 17.7.1. Company Overview 17.7.2. Product Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8 ASTRAZENECA 17.8.1. Company Overview 17.8.2. Product Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9 SERUM INSTITUTE OF INDIA PVT. LTD. 17.9.1. Company Overview 17.9.2. Product Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10 BAVARIAN NORDIC 17.10.1. Company Overview 17.10.2. Product Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 17.11 MITSUBISHI TANABE PHARMA CORP. 17.11.1. Company Overview 17.11.2. Product Portfolio 17.11.3. SWOT Analysis 17.11.4. Financial Overview 17.11.5. Strategic Overview 17.12 DAIICHI SANKYO CO. LTD. 17.12.1. Company Overview 17.12.2. Product Portfolio 17.12.3. SWOT Analysis 17.12.4. Financial Overview 17.12.5. Strategic Overview 17.13 PANACEA BIOTEC LTD. 17.13.1. Company Overview 17.13.2. Product Portfolio 17.13.3. SWOT Analysis 17.13.4. Financial Overview 17.13.5. Strategic Overview 17.14 BIOLOGICAL E LTD. 17.14.1. Company Overview 17.14.2. Product Portfolio 17.14.3. SWOT Analysis 17.14.4. Financial Overview 17.14.5. Strategic Overview 17.15 BHARAT BIOTECH 17.15.1. Company Overview 17.15.2. Product Portfolio 17.15.3. SWOT Analysis 17.15.4. Financial Overview 17.15.5. Strategic Overview 18. Impact of COVID-19 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations 19. FutureWise SME key takeaway points for Client
1. Market Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Years Considered for the Study
1.3.2 Market Covered
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2. Research Methodology
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.2 Market Size Estimation
2.3 Market Breakdown and Data Triangulation
2.4 Assumptions for the Study
3. Executive Summary
3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights
4. Global Vaccines Market Variables, Trends & Scope
4.1. Market Lineage Outlook
4.2. Penetration and Growth Prospect Mapping
4.3. Industry Value Chain Analysis
4.4. Cost Analysis Breakdown
4.5. Technology Overview
4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards And Compliances
5. Market Overview
5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Pharmaceutical Manufacturers on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Global Vaccines Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Global Vaccines Market , By Technology Historical Analysis and Forecast 2022-2028 (USD Million)
7.1. Conjugate Vaccines
7.2. Inactive and Subunit Vaccines
7.3. Live Attenuated Vaccines
7.4. Recombinant Vaccines
7.5. Toxoid Vaccines
8. Global Vaccines Market , By Type Historical Analysis and Forecast 2022-2028 (USD Million)
8.1. Monovalent Vaccines 8.2. Multivalent Vaccines
9. Global Vaccines Market , By Disease Indication Historical Analysis and Forecast 2022-2028 (USD Million)
9.1. Pneumococcal Disease
9.2. DTP
9.3. Influenza
9.4. HPV
9.5. Meningococcal Disease
9.6. Polio
9.7. Hepatitis
9.8. Rotavirus
9.9. MMR
9.10. Varicella
9.11. Herpes Zoster
9.12. Others
10. Global Vaccines Market , By Route of Administration Historical Analysis and Forecast 2022-2028 (USD Million)
10.1. Intramuscular and Subcutaneous Administration
10.2. Oral Administration
10.3. Others
11. Global Vaccines Market , By Patient Type Historical Analysis and Forecast 2022-2028 (USD Million)
11.1. Pediatric Patients
11.2. Adult Patients
11.3. Others
12. North America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
12.1. Introduction
12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
12.2.1. U.S.A
12.2.2. Canada
12.3. Market Size (USD Million) Forecast for North America 2022-2028
13. Latin America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
13.1. Introduction
13.2. Regional Market Trends
13.3. Historical Market Size (USD Million) Analysis By Country, 2016-2020
13.3.1. Brazil
13.3.2. Mexico
13.3.3. Argentina
13.3.4. Rest of Latin America
13.4. Market Size (USD Million) Forecast for Latin America 2022-2028
14. Europe Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
14.1. Introduction
14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
14.2.1. Germany
14.2.2. U.K
14.2.3. France
14.2.4. Italy
14.2.5. Spain
14.2.6. Russia
14.2.7. Poland
14.2.8. Switzerland
14.2.9. Rest of Western Europe
15. Asia Pacific Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
15.1. Introduction
15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
15.2.1. Japan
15.2.2. China
15.2.3. Singapore
15.2.4. India
15.2.5. Australia and New Zealand
15.2.6. ASEAN
15.2.7. South Korea
15.2.8. Rest of Asia Pacific
15.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
16. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
16.1. Introduction
16.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
16.2.1. GCC 16.2.2. Israel 16.2.3. South Africa 16.2.4. Rest of MEA
16.3. Market Size (USD Million) Forecast for MEA 2022-2028
17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)
17.1 GLAXOSMITHKLINE PLC
17.1.1. Company Overview
17.1.2. Product Portfolio
17.1.3. SWOT Analysis
17.1.4. Financial Overview
17.1.5. Strategic Overview
17.2 PFIZER INC.
17.2.1. Company Overview
17.2.2. Product Portfolio
17.2.3. SWOT Analysis
17.2.4. Financial Overview
17.2.5. Strategic Overview
17.3 MERCK & CO. INC.
17.3.1. Company Overview
17.3.2. Product Portfolio
17.3.3. SWOT Analysis
17.3.4. Financial Overview
17.3.5. Strategic Overview
17.4 SANOFI PASTEUR SA
17.4.1. Company Overview
17.4.2. Product Portfolio
17.4.3. SWOT Analysis
17.4.4. Financial Overview
17.4.5. Strategic Overview
17.5 CSL LIMITED
17.5.1. Company Overview
17.5.2. Product Portfolio
17.5.3. SWOT Analysis
17.5.4. Financial Overview
17.5.5. Strategic Overview
17.6 EMERGENT BIOSOLUTIONS
17.6.1. Company Overview
17.6.2. Product Portfolio
17.6.3. SWOT Analysis
17.6.4. Financial Overview
17.6.5. Strategic Overview
17.7 JOHNSON & JOHNSON
17.7.1. Company Overview
17.7.2. Product Portfolio
17.7.3. SWOT Analysis
17.7.4. Financial Overview
17.7.5. Strategic Overview
17.8 ASTRAZENECA
17.8.1. Company Overview
17.8.2. Product Portfolio
17.8.3. SWOT Analysis
17.8.4. Financial Overview
17.8.5. Strategic Overview
17.9 SERUM INSTITUTE OF INDIA PVT. LTD.
17.9.1. Company Overview
17.9.2. Product Portfolio
17.9.3. SWOT Analysis
17.9.4. Financial Overview
17.9.5. Strategic Overview
17.10 BAVARIAN NORDIC
17.10.1. Company Overview
17.10.2. Product Portfolio
17.10.3. SWOT Analysis
17.10.4. Financial Overview
17.10.5. Strategic Overview
17.11 MITSUBISHI TANABE PHARMA CORP.
17.11.1. Company Overview
17.11.2. Product Portfolio
17.11.3. SWOT Analysis
17.11.4. Financial Overview
17.11.5. Strategic Overview
17.12 DAIICHI SANKYO CO. LTD.
17.12.1. Company Overview
17.12.2. Product Portfolio
17.12.3. SWOT Analysis
17.12.4. Financial Overview
17.12.5. Strategic Overview
17.13 PANACEA BIOTEC LTD.
17.13.1. Company Overview
17.13.2. Product Portfolio
17.13.3. SWOT Analysis
17.13.4. Financial Overview
17.13.5. Strategic Overview
17.14 BIOLOGICAL E LTD.
17.14.1. Company Overview
17.14.2. Product Portfolio
17.14.3. SWOT Analysis
17.14.4. Financial Overview
17.14.5. Strategic Overview
17.15 BHARAT BIOTECH
17.15.1. Company Overview
17.15.2. Product Portfolio
17.15.3. SWOT Analysis
17.15.4. Financial Overview
17.15.5. Strategic Overview
18. Impact of COVID-19
18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations
19. FutureWise SME key takeaway points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics